Plain-English translation of NCT06853912 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing psilocybin — a psychedelic compound — paired with dedicated psychological support to treat people who are struggling with both PTSD and alcohol use disorder. You would receive preparation sessions, a supervised dose of the medication or placebo in a clinical setting, and follow-up therapy sessions over about 6 weeks. The study wants to learn whether this combination is safe and whether it might help reduce symptoms of trauma and alcohol dependence.
Current treatments don't always work well for people dealing with both PTSD and alcohol use disorder at the same time. Early research suggests that psychedelic-assisted therapy may help with these conditions, but no one has studied this combination treatment before — so this trial is designed to find out if this approach is safe and could help.
Over about 6 weeks, you would attend two online preparation sessions with two facilitators, then come to a clinical setting for a supervised 6–8 hour session where you would receive either the medication or placebo. You would need a trusted person to pick you up and stay with you that night. After that, you would have three more online follow-up sessions with the same facilitators to discuss your experience. The study will follow you for about 26–32 weeks total, with check-in visits and surveys at different timepoints to see how you are doing.
AI-generated summary from trial data · Aug 18, 2026 · Not medical advice
United States